2. Academic Validation
  3. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26)

NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26)

  • Biochem Biophys Res Commun. 2009 Apr 17;381(4):491-5. doi: 10.1016/j.bbrc.2009.02.069.
Mina Song 1,  Jae Eun Park,  Sung Goo Park,  Do Hee Lee,  Hyung-Kyoon Choi,  Byoung Chul Park,  Seong Eon Ryu,  Jae Hoon Kim,  Sayeon Cho
Affiliations

Affiliation

  • 1 Chung-Ang University, Dongjak-Gu, Heuk-suk Dong, Seoul, Republic of Korea.
PMID: 19233143 DOI: 10.1016/j.bbrc.2009.02.069
Abstract

Protein phosphorylation plays critical roles in many regulatory mechanisms controlling cell activities and thus involved in various diseases. The cellular equilibrium of phosphorylation is regulated through the actions of protein kinases and phosphatases. Therefore, these regulatory proteins have emerged as promising targets for drug development. In this study, we screened Protein tyrosine phosphatases (PTPs) by in vitro Phosphatase assays to identify PTPs that are inhibited by 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877), a potent inhibitor of SHP-1 and SHP-2 PTPs. Phosphatase activity of dual-specificity protein Phosphatase 26 (DUSP26) was decreased by the inhibitor in a dose-dependent manner. Kinetic studies with NSC-87877 and DUSP26 revealed a competitive inhibition. NSC-87877 effectively inhibited DUSP26-mediated dephosphorylation of p38, a member of mitogen-activated protein kinase (MAPK) family. Since DUSP26 is involved in survival of anaplastic thyroid Cancer (ATC) cells, NSC-87877 could be a therapeutic reagent for treating ATC.

Figures
Products